Latest Actelion Ltd (ALIOF) Headlines Myriad
Post# of 5
Posted On: 03/08/2014 6:33:20 PM
Latest Actelion Ltd (ALIOF) Headlines
Myriad Genetics Up on Prolaris Data; Aims Reimbursement - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 1:50PM CST
Recently, favorable data from Myriad Genetics' PROCEDE 500 study was published in the journal Current Medical Research and Opinion.
Actelion Gains on QIDP and Fast Track Status - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 4:10PM CST
Shares of Actelion gained 4.7% on the announcement of the receipt of QIDP and Fast Track designations for its CDAD candidate, cadazolid.
Transition Therapeutics (TTHI) Jumps: Stock Moves 7.6% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 8:46AM CST
Transition Therapeutics was a big mover last session, with shares rising nearly 8%.
UCB Misses Earnings Ests, Revs In Line - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 27, 12:32PM CST
UCB reported 2013 earnings per share of $2.56, missed the Zacks Consensus Estimate of $2.84.
Shares Fall as Aegerion Posts Wider-than-Expected Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 27, 12:26PM CST
Aegerion Pharma reported 4Q13 net loss per share of 47 cents, wider than the Zacks Consensus Estimate of a loss of 28 cents
Actelion's novel antibiotic cadazolid receives US FDA Qualified Infectious Disease Product designation for the treatment of Clostridium difficile-associated diarrhea
Thomson Reuters ONE - Thu Feb 27, 10:35AM CST
Actelion Pharmaceuticals Ltd / Actelion's novel antibiotic cadazolid receives US FDA Qualified Infectious Disease Product designation for the treatment of Clostridium difficile-associated diarrhea . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Encouraging News from Pfizer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 25, 4:25PM CST
Pfizer recently released encouraging top-line results from a randomized, placebo-controlled trial, CAPiTA on pneumonia vaccine Prevenar 13
NewLink Genetics (NLNK) Jumps: Stock Moves 8.2% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 25, 8:46AM CST
NewLink Genetics was a big mover last session, with shares rising over 8%.
Synta Pharmaceuticals (SNTA) Catches Eye: Stock Rises 8.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 25, 8:25AM CST
Synta Pharmaceuticals was a big mover last session, with shares rising nearly 9%.
Amarin's Vascepa Gets 3-Year Exclusivity - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 24, 4:20PM CST
Amarin announced that Vascepa was given 3 years of marketing exclusivity by FDA in connection with the MARINE indication.
Vertex' Kalydeco Approved for an Additional Indication - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 24, 12:00PM CST
Vertex Pharma received encouraging news when the FDA approved Kalydeco for an additional indication.
Encouraging Data on Bristol-Myers/Pfizer's Eliquis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 24, 10:50AM CST
Eliquis performed encouragingly in a late stage study.
Retrophin (RTRX) Jumps: Stock Moves 14.3% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 24, 8:46AM CST
Retrophin was a big mover last session, with shares rising over 14%.
Stemline Therapeutics (STML) Worth Watching: Stock Rises 8.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 24, 8:25AM CST
Stemline Therapeutics was a big mover last session, with shares rising over 8%.
Should You Get Rid of WellCare (WCH) Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 24, 7:58AM CST
WellCare has witnessed a significant price decline in the past four weeks with negative earnings estimate revisions for the current quarter and the current year
Bayer Progresses with Stivarga - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 21, 4:00PM CST
Bayer announced the commencement of the patient enrolment process for a phase III study on Stivarga.
Raptor Soars on Positive RP103 Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 21, 3:30PM CST
Raptor soared almost 14.9% after the company announced encouraging results from a study on RP103.
Omeros Doses First Patient in a Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 20, 5:00PM CST
Omeros announced that the first patient has been dosed in a second phase II study on candidate, OMS824
Pipeline Progress at Bayer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 20, 4:00PM CST
Bayer announced the initiation of the phase III EINSTEIN CHOICE study on Xarelto.
The Medicines Co Posts Lower Y/Y Q4 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 20, 9:40AM CST
The Medicines Co.'s fourth-quarter earnings of 26 cents per share were well below the year-ago earnings of 52 cents per share.
Myriad Genetics Up on Prolaris Data; Aims Reimbursement - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 1:50PM CST
Recently, favorable data from Myriad Genetics' PROCEDE 500 study was published in the journal Current Medical Research and Opinion.
Actelion Gains on QIDP and Fast Track Status - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 4:10PM CST
Shares of Actelion gained 4.7% on the announcement of the receipt of QIDP and Fast Track designations for its CDAD candidate, cadazolid.
Transition Therapeutics (TTHI) Jumps: Stock Moves 7.6% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 8:46AM CST
Transition Therapeutics was a big mover last session, with shares rising nearly 8%.
UCB Misses Earnings Ests, Revs In Line - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 27, 12:32PM CST
UCB reported 2013 earnings per share of $2.56, missed the Zacks Consensus Estimate of $2.84.
Shares Fall as Aegerion Posts Wider-than-Expected Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 27, 12:26PM CST
Aegerion Pharma reported 4Q13 net loss per share of 47 cents, wider than the Zacks Consensus Estimate of a loss of 28 cents
Actelion's novel antibiotic cadazolid receives US FDA Qualified Infectious Disease Product designation for the treatment of Clostridium difficile-associated diarrhea
Thomson Reuters ONE - Thu Feb 27, 10:35AM CST
Actelion Pharmaceuticals Ltd / Actelion's novel antibiotic cadazolid receives US FDA Qualified Infectious Disease Product designation for the treatment of Clostridium difficile-associated diarrhea . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Encouraging News from Pfizer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 25, 4:25PM CST
Pfizer recently released encouraging top-line results from a randomized, placebo-controlled trial, CAPiTA on pneumonia vaccine Prevenar 13
NewLink Genetics (NLNK) Jumps: Stock Moves 8.2% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 25, 8:46AM CST
NewLink Genetics was a big mover last session, with shares rising over 8%.
Synta Pharmaceuticals (SNTA) Catches Eye: Stock Rises 8.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 25, 8:25AM CST
Synta Pharmaceuticals was a big mover last session, with shares rising nearly 9%.
Amarin's Vascepa Gets 3-Year Exclusivity - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 24, 4:20PM CST
Amarin announced that Vascepa was given 3 years of marketing exclusivity by FDA in connection with the MARINE indication.
Vertex' Kalydeco Approved for an Additional Indication - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 24, 12:00PM CST
Vertex Pharma received encouraging news when the FDA approved Kalydeco for an additional indication.
Encouraging Data on Bristol-Myers/Pfizer's Eliquis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 24, 10:50AM CST
Eliquis performed encouragingly in a late stage study.
Retrophin (RTRX) Jumps: Stock Moves 14.3% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 24, 8:46AM CST
Retrophin was a big mover last session, with shares rising over 14%.
Stemline Therapeutics (STML) Worth Watching: Stock Rises 8.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 24, 8:25AM CST
Stemline Therapeutics was a big mover last session, with shares rising over 8%.
Should You Get Rid of WellCare (WCH) Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 24, 7:58AM CST
WellCare has witnessed a significant price decline in the past four weeks with negative earnings estimate revisions for the current quarter and the current year
Bayer Progresses with Stivarga - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 21, 4:00PM CST
Bayer announced the commencement of the patient enrolment process for a phase III study on Stivarga.
Raptor Soars on Positive RP103 Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 21, 3:30PM CST
Raptor soared almost 14.9% after the company announced encouraging results from a study on RP103.
Omeros Doses First Patient in a Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 20, 5:00PM CST
Omeros announced that the first patient has been dosed in a second phase II study on candidate, OMS824
Pipeline Progress at Bayer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 20, 4:00PM CST
Bayer announced the initiation of the phase III EINSTEIN CHOICE study on Xarelto.
The Medicines Co Posts Lower Y/Y Q4 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 20, 9:40AM CST
The Medicines Co.'s fourth-quarter earnings of 26 cents per share were well below the year-ago earnings of 52 cents per share.
(0)
(0)